|
Spexis AG / Key word(s): Statement Spexis to host business update conference call on October 9, 2023 06.10.2023 / 07:30 CET/CEST
Spexis to host business update conference call on October 9, 2023 Allschwil, Switzerland, October 6, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: +33 0805102207 International Toll Free +1 412-317-6789 Event Title: Spexis AG – Business Update Conference Call The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g After the call, a replay of the webcast will be available via the above link. About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact: For Investors: Or Stephen Jasper
For Media:
End of Media Release |
Space-grown stem cells show promise for accelerating biotherapies
Stem cells grown in microgravity aboard the International Space Station (ISS) have unique qualities that could one day help accelerate new biotherapies and heal complex
November 4, 2024